
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp. is positioned favorably in the biopharmaceutical sector, primarily due to its robust vaccine response rates for its 100ug shingles vaccine candidate, which are comparable to those of Shingrix while exhibiting significantly better tolerability. The encouraging results related to the tolerability and CD4+ T-cell responses for the candidate Z-1018 further strengthen the company's outlook in the vaccine market. These positive developments align with Dynavax's focus on leveraging its innovative Toll-like Receptor Immune Modulation Platform, solidifying its potential for revenue growth from its novel vaccines and established products like HEPLISAV-B and CpG 1018.
Bears say
Dynavax Technologies Corp faces significant risks related to the efficacy and safety of its clinical candidates, as failures could hinder regulatory approval and subsequent commercialization, negatively impacting revenue potential. Additionally, market conditions, strong competition, and internal factors may further complicate the commercialization of its proprietary candidates, putting Dynavax at a strategic disadvantage. The possibility of unsuccessful partnership negotiations for its product candidates also raises concerns regarding future growth and financial stability, contributing to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares